Background/Objectives: Although oxytocin administration is recommended for delayed labor progress, there is no consensus over the preferred optimal dose of oxytocin. We aimed to perform a meta-analysis of pregnancy outcomes comparing high-dose versus low-dose oxytocin regimens for augmentation of delayed labor. Methods: PubMed, Embase, and Cochrane databases were systematically searched for studies comparing high-dose with low-dose oxytocin for labor augmentation from inception up to May 2023. The outcomes assessed were cesarean rate, instrumental delivery rate, postpartum hemorrhage, neonatal death, and uterine tachysystole. Subgroup analysis was performed with randomized controlled trials (RCTs) and propensity-matched studies. Statistical analysis was performed using Rstudio. Heterogeneity was assessed with I² statistics, and a random-risk effect was used if I² > 50%. Results: Twenty-one studies met inclusion criteria, and eighteen were RCTs. A total of 14.834 patients were included, of whom 7.921 (53.3%) received high-dose and 6.913 (46.6%) received low-dose oxytocin during labor augmentation. No statistical differences were found in cesarean delivery, neonatal mortality, postpartum hemorrhage and vaginal instrumentation rate. However, uterine tachysystole incidence was significantly higher with high-dose oxytocin (95% Cl, 1.30–1.94, p = 0.3; 0.6; I² = 9%). Conclusions: Labor augmentation with a low-dose oxytocin regimen is effective as with a high-dose regimen, but with significantly less uterine tachysystole events, which can lead to intrauterine and neonatal complications. Our findings suggest that a low-dose regimen may be safe and effective for labor augmentation in medical practice.

Urinary bladder cancer (UBC), the tenth most common globally with a male predominance, has its risk factors like smoking and single nucleotide polymorphisms (SNPs), yet the MYC gene's role, especially the rs9642880 GT/TT polymorphism on chromosome 8q24.21, in cancer susceptibility is underexplored. We searched in Medline, Scopus and Web of Science databases for relevant studies. Odds ratios (OR) with 95% confidence intervals (CIs) were computed using DerSimonian and Laird random-effect models. Heterogeneity was assessed using I² statistics. Statistical analyses were performed using R, version 4.4.2. Data from 53,957 subjects was analyzed, including 8,002 UBC patients and 45,955 controls, with median age ranging from 44.5 to 68.7 years. We found significant association between the rs9642880 GT/TT polymorphism and increased UBC risk (OR 1.249, 95% CI 1.188-1.297, p < 0.001). This association was consistent across American (OR 1.43 95% CI 1.20-1.70), Asian (OR 1.25 95% CI 1.17-1.34), and Caucasian (OR 1.21 95% CI 1.13-1.29) ethnic groups, with low heterogeneity (I² = 0%). Subgroup analyses by genotyping method and source of control further supported these results. This meta-analysis provides robust evidence that the T allele of the rs9642880 polymorphism in the MYC gene significantly increases susceptibility to UBC across Asian, American, and Caucasian populations.